{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:35:48Z","timestamp":1763642148127,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.rdc.2016.09.008","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T03:05:39Z","timestamp":1480043139000},"page":"79-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Malignancy and Janus Kinase Inhibition"],"prefix":"10.1016","volume":"43","author":[{"given":"Padmapriya","family":"Sivaraman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2016.09.008_bib1","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/ard.2008.100008","article-title":"Adverse events of low to medium dose oral glucocorticoids in inflammatory diseases: a meta-analysis","volume":"68","author":"Hoes","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.008_bib2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/keu339","article-title":"Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice","volume":"54","author":"Fortunet","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2016.09.008_bib3","first-page":"807","article-title":"Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice","volume":"27","author":"Seror","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2016.09.008_bib4","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/ard.2009.111807","article-title":"Anti tumour necrosis factor alpha therapy in patients with rheumatoid arthritis results in a significant and long lasting decrease of concomitant glucocorticoid treatment","volume":"68","author":"Navmann","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2016.09.008_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11926-009-0054-9","article-title":"Intracellular signal pathways: potential for therapies","volume":"11","author":"Mavers","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"13","key":"10.1016\/j.rdc.2016.09.008_bib6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.rdc.2016.09.008_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.0105-2896.2005.00220.x","article-title":"Jak 3, severe combined immunodeficiency, and a new class of immunosuppressive drugs","volume":"203","author":"Pesu","year":"2005","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.rdc.2016.09.008_bib9","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.rdc.2016.09.008_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase Jak 2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.008_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"New Eng J Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2006-11-059246","article-title":"Expression of Tyk 2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of TH1 cell differentiation","volume":"110","author":"Tokumasa","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rdc.2016.09.008_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.18773\/austprescr.2014.061","article-title":"Janus kinase inhibitors: mechanisms of action","volume":"37","author":"Kubler","year":"2014","journal-title":"Aust Prescr"},{"issue":"2","key":"10.1016\/j.rdc.2016.09.008_bib14","first-page":"318","article-title":"The mechanism of action of tofacitinib \u2013 an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2016.09.008_bib16","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A\u00a0meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2016.09.008_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib18","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systemic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.008_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2016.09.008_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.rdc.2004.01.007","article-title":"Association between rheumatoid arthritis and malignancy","volume":"30","author":"Chakravarthy","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rdc.2016.09.008_bib21","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib22","unstructured":"National Cancer Institute. Surveillance, epidemiology and end results. Available at: http:\/\/seer.cancer.gov\/."},{"key":"10.1016\/j.rdc.2016.09.008_bib23","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti tumour necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy. A meta-analysis","volume":"308","author":"Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2016.09.008_bib25","first-page":"1","article-title":"Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries","volume":"9","author":"Codreanu","year":"2015","journal-title":"Biologics"},{"key":"10.1016\/j.rdc.2016.09.008_bib26","unstructured":"FDA Advisory Committee meeting briefing documents, FDA white Oak conference center, Maryland, May 9th, 2012."},{"issue":"5","key":"10.1016\/j.rdc.2016.09.008_bib27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.008_bib28","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.008_bib30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14397595.2014.995875","article-title":"Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study","volume":"25","author":"Tanaka","year":"2015","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.008_bib31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/art.33419","article-title":"A\u00a0phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone","volume":"64","author":"Kremer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomized phase 3 Trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.rdc.2016.09.008_bib33","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"Vollenhoven","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from twenty four month phase III randomized radiographic study","volume":"65","author":"Van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open label, long term extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.008_bib39","first-page":"1215","article-title":"Tofacitinib an oral Janus kinase inhibitor, as monotherapy or with background methotrexate in Japanese patients with rheumatoid arthritis: a phase 2\/3 long-term extension study","volume":"63","author":"Yamanaka","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2016.09.008_bib41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1136\/ard.2004.033993","article-title":"Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.008_bib42","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin\u2019s lymphoma","volume":"122","author":"Kippers","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.rdc.2016.09.008_bib43","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2008.07.010","article-title":"Peripheral T\u00a0cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Vose","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.rdc.2016.09.008_bib44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1158\/1055-9965.EPI-05-0958","article-title":"Incidence of non-Hodgkin\u2019s lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was","volume":"15","author":"Sandin","year":"2006","journal-title":"Cancer Epidemiol biomarkers prev"},{"key":"10.1016\/j.rdc.2016.09.008_bib45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10428194042000198849","article-title":"Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors","volume":"45","author":"Chang","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.rdc.2016.09.008_bib46","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"Risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"Zintzaras","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rdc.2016.09.008_bib47","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.10939","article-title":"Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives","volume":"48","author":"Ekstrom","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00002281-200405000-00014","article-title":"Rheumatoid arthritis and malignant lymphomas","volume":"16","author":"Baecklund","year":"2004","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2016.09.008_bib49","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.rdc.2016.09.008_bib50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","article-title":"Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis","volume":"168","author":"Bernatsky","year":"2008","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2016.09.008_bib51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2016.09.008_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.critrevonc.2005.03.015","article-title":"Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.rdc.2016.09.008_bib53","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Post transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.rdc.2016.09.008_bib54","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rdc.2016.09.008_bib55","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.rdc.2016.09.008_bib56","unstructured":"Curtis JR, Lee EB, Martin G, et\u00a0al. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical program, 16th annual European congress of rheumatology, Rome (Italy), June 10-13, 2015."},{"key":"10.1016\/j.rdc.2016.09.008_bib57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.rdc.2016.09.008_bib58","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rdc.2016.09.008_bib59","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.008_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","article-title":"Incidence of overall and site specific cancers in TNF alpha inhibitor treated patients with rheumatoid arthritis and other arthritides\u2013a follow up study from the DANBIO Registry","volume":"72","author":"Dreyer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2016.09.008_bib61","doi-asserted-by":"crossref","first-page":"e48991","DOI":"10.1371\/journal.pone.0048991","article-title":"Cancer risk and Anti TNF alpha at recommended doses in adult rheumatoid arthritis: a meta analysis with intention to treat and per protocol analyses","volume":"7","author":"Moulis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2016.09.008_bib62","doi-asserted-by":"crossref","first-page":"i262","DOI":"10.1136\/bmj.i262","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor treatment and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden","volume":"352","author":"Raaschou","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.rdc.2016.09.008_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rdc.2016.09.008_bib64","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.semarthrit.2007.08.006","article-title":"Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population","volume":"37","author":"Abasolo","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib65","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2016.09.008_bib66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24\u00a0weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2016.09.008_bib67","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.150613","article-title":"Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12\u00a0week, double blind, randomized placebo controlled study","volume":"43","author":"Tanaka","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2016.09.008_bib68","doi-asserted-by":"crossref","unstructured":"Kremer JM, Keystone EC, Emery P, et\u00a0al. Selective Jak 1 inhibitor in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy. 2015 ACR\/ARHP Annual Meeting. [abstract: 14L].","DOI":"10.1136\/annrheumdis-2016-eular.1448"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1630059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1630059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:15:38Z","timestamp":1760181338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X1630059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0889857X1630059X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2016.09.008","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy and Janus Kinase Inhibition","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2016.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}